The Standing Committee on Health (HESA) of the House of Commons met on Thursday, April 27, 2023, to begin its study of the Patented Medicine Prices Review Board (PMPRB). The Committee first heard from the Minister of Health, the Honourable Jean-Yves Duclos. The Minister’s appearance was followed by witnesses from the Department of Health and the Department of Justice, as well as Mélanie Bourassa Forcier, Professor at the University of Sherbrooke and the former Acting Chair of the PMPRB.
The Committee will reconvene on May 2, 2023, to hear from Matthew Herder, Associate Professor at Dalhousie University and former board member of the PMPRB, as well as the current Executive Director of the PMPRB, Douglas Clark.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Canada’s Drug Agency releases new resource and data on drug approval and reimbursement pathway
Canada’s Drug Agency (CDA-AMC) published data on Canada’s drug system as part of the Data Systems and Analytics program.Read More -
PMPRB update: Guidelines for PMPRB Staff come into effect January 1, 2026; 2024 Annual Report
On January 1, 2026, the Guidelines for PMPRB Staff will come into effect. In November, the Patented Medicine Prices Review Board (PMPRB) held information sessions on the Guidelines to share technical ...Read More -
2025 highlights in Canadian life sciences IP and regulatory law
In 2025, the Rx IP Update team at Smart & Biggar reported on a number of developments in Canadian life sciences IP and regulatory law.Read More
